-
-
-
-
-
-
-
Benchmark Reiterates Buy Rating on XOMA, Ltd. (XOMA) Despite Rezolute Setback
-
-
-
-
-
-
-
XOMA, Ltd. (XOMA) PT Raised to $58 at Leerink Partners
-
-
-
-
-
-
-
XOMA, Ltd. (XOMA) PT Raised to $50 at Benchmark
-
-
-
-
-
-
-
Turnstone Biologics (TSBX) to be Acquired by XOMA Royalty (XOMA) for $0.34 in Cash Per Share Plus a Contingent Value Right
-
-
-
-
-
-
-
XOMA, Ltd. (XOMA) PT Lowered to $104 at H.C. Wainwright
-
-
-
-
-
-
-
XOMA (XOMA) Announces FDA Approval of MIPLYFFA for Patients with Niemann-Pick Disease Type C
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

